Filing Flows › Health Care › Jaguar Health (JAGX)
Jaguar Health (JAGX) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 19, 2026 · Jaguar Health (JAGX) Q2 2026 earnings results →
Q2 2026 Revenue down 59% year over year to $1.2M · operating margin -620.2%
Jaguar Health made $1.2M in Q2 2026 (-59% Y/Y): Product $1.2M, License $43K. Operating margin -620.2%, net loss $12.8M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 19, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.2M in Q2 2026, down 59% year over year and down 94% from the previous quarter. Product was the largest line at 96% of revenue. Product lost $1.8M year over year (down 60%), 100% of the total change.
Operating costs exceeded revenue by $7.6M, an operating margin of -620.2%. Total costs fell 20% while revenue fell 59%. The fastest-growing cost line was Cost of revenue (+96%). The quarter ended with a net loss of $12.8M, after a profit of $8.7M the previous quarter. Minority interests bore $101K of it: to shareholders the quarter was a loss of $12.7M.
Operating cash flow was −$5.3M. Non-cash charges added back $473K of depreciation and amortization and $171K of share-based compensation. Working capital and other items added $6.8M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 19, 2026 | $1.2M | -59% | -620.2% | −$12.8M | −$5.3M |
| Q1 2026 | 10-Q | May 20, 2026 | $20.3M | +816% | 50.2% | $8.7M | $8.8M |
| Q4 2025 | 10-K | Apr 7, 2026 | $3.2M | -8% | -656.6% | −$23.2M | −$5.5M |
| Q3 2025 | 10-Q | Nov 14, 2025 | $3.1M | -0.8% | -234.8% | −$9.6M | −$4.7M |
| Q2 2025 | 10-Q | Aug 14, 2025 | $3.0M | +10% | -268.8% | −$10.6M | −$6.2M |
| Q1 2025 | 10-Q | May 15, 2025 | $2.2M | -6% | -425.5% | −$10.6M | −$7.3M |
| Q4 2024 | 10-K | Mar 31, 2025 | $3.5M | +53% | -232.5% | −$10.2M | −$7.8M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Jaguar Health
Jaguar Health, Inc. (“Jaguar”) develops novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal (“GI”) disease states. Jaguar family companies Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including microvillus inclusion disease and short bowel syndrome. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
In its own words, from its 8-K, filed Aug 19, 2026.
Jaguar Health against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -59% against the peers' median +7%. Operating margin: -620.2% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| JAGX Jaguar Health | Q2 2026 | $1.2M | -59% | -620.2% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Jaguar Health 10-Q on SEC EDGAR · CIK 1585608 · Pharmaceutical Preparations
More on JAGX
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results